March 8th, 2011
RESEARCH TRIANGLE PARK, NC – Bioptigen Inc., a company that has developed in vivo optical imaging systems that enables real-time, noninvasive imaging of internal tissue microstructure, has raised $1.5 million from a single investor, according to a regulatory filing.
Bioptigen is a spin-out of the Duke University Biomedical Engineering Department. Bioptigen was incorporated in North Carolina in August, 2004, to commercialize technologies originating in the laboratories of Professor Joseph Izatt.
The company’s technology is based on the science of Optical Coherence Tomography, an imaging system similar in function to ultrasound, but using low-power light rather than sound waves.
OCT offers resolution 100-times finer than standard ultrasound, suitable for analyzing tissue microstructure with features smaller than 4 micrometer.
Bioptigen sold $542,500 in mixed securities in 2007.
The company disclosed the current raise in a filing with the US Securities and Exchange Commission.